Bloomberg News

Onyx Potential Sale Talks Involve Multiple Companies, CEO Says

August 09, 2013

Onyx Pharmaceuticals Inc. (ONXX:US), the biotechnology company said to have rebuffed an initial takeover bid from Amgen Inc. (AMGN:US), is involved with several potential purchasers, Chief Executive Officer N. Anthony Coles said.

“The process is ongoing with multiple parties currently engaged in discussions,” Coles said yesterday during a conference call after the company released second-quarter earnings. He said the South San Francisco, California-based company wouldn’t comment further.

Onyx’s suitors are interested in Kyprolis, a cancer drug approved last year for some patients with multiple myeloma. The treatment may draw $3 billion in revenue by 2022, according to analysts’ estimates (ONXX:US) compiled by Bloomberg. A deal would give a purchaser a likely boost in sales as Kyprolis grows.

For Amgen, the therapy would supplement a roster of products aimed at helping cancer patients with their treatment with a medicine that targets cancer itself. Amgen, based in Thousand Oaks, California, is the world’s biggest biotechnology company by revenue. The company is said to have boosted its offer for Onyx to $130 a share from $120 a share, Bloomberg News reported Aug. 6.

Onyx shares gained 1.2 percent to $129 at 5:32 p.m. New York time after declining less than 1 percent to $127.42 at the close. Amgen declined 1.8 percent to close at $110.38.

AstraZeneca Plc, Pfizer Inc. (PFE:US) and Novartis AG (NOVN) had also expressed interest, Bloomberg reported in July.

Bayer Partnership

Onyx also sells Nexavar for liver and kidney cancer in partnership with Germany’s Bayer AG. (BAYN) Onyx generated $362 million in 2012 revenue, with 80 percent coming from Nexavar and the stomach-cancer treatment Stivarga. The company gets a 20 percent royalty on Stivarga from Bayer, which has said it expects the medicine to be a bestseller.

Earlier, Onyx reported a second-quarter loss (ONXX:US) of 40 cents per share, excluding certain items, compared with a loss of 41 cents from 16 analysts’ estimates compiled by Bloomberg. Revenue of $153 million topped analysts’ estimates of $152 million.

Quarterly sales of Kyprolis were $61 million and the company reported another $10 million in revenue from the drug’s inventory at distributors that hadn’t yet been shipped to doctors and hospitals, the company said in its statement.

To contact the reporter on this story: Drew Armstrong in New York at darmstrong17@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Steve Ballmer, Power Forward
LIMITED-TIME OFFER SUBSCRIBE NOW

Companies Mentioned

  • AMGN
    (Amgen Inc)
    • $137.51 USD
    • 3.82
    • 2.78%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus